Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy
Executive Summary
Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.
You may also be interested in...
US Prescribers Embrace Oncology Biosimilars; How Will Humira Follow-Ons Fare?
Rheumatologists may be more cautious about prescribing biosimilars to Humira than they have been for biosimilars to Avastin and Herceptin. But pharmacy benefit managers will have more influence over Humira biosimilars, which adds a new dynamic to the follow-on market.
Amgen Sees A Vibrant US Biosimilars Market
Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.
Amgen Sees A Vibrant Biosimilars Market As Its Business Pushes Into Blockbuster Territory
Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.